secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000886163-23-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q2 adjusted EPS $1.42 beats; raises FY2023 adjusted EPS outlook to $4.85-$5.00
--------------------------------------------------------------------------------

- Q2 adjusted net income from continuing ops $25.1M ($1.42 diluted) vs $7.4M ($0.43) prior year; GAAP EPS $0.13.
- Royalties grew 15% to $20.4M; core Captisol sales $5.2M vs $3.3M. No COVID-19 Captisol sales vs $26.2M.
- Cash $219M; debt-free after May 2023 convertible note payoff. $50M share repurchase program authorized.
- FY2023 guidance: revenue $124-128M (reaffirmed); adjusted EPS raised to $4.85-$5.00 from $4.60-$4.75.
- Agreed to purchase Novan assets for $15M cash plus DIP financing; Berdazimer gel NDA PDUFA Jan 5, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/0000886163-23-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000047/lgnd-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000886163-23-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer